NYSE:VAR - Varian Medical Systems Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $148.28
  • Forecasted Upside: -15.68 %
  • Number of Analysts: 9
  • Breakdown:
  • 3 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$175.85
▲ +0.15 (0.09%)
1 month | 3 months | 12 months
Get New Varian Medical Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VAR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VAR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$148.28
▼ -15.68% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Varian Medical Systems in the last 3 months. The average price target is $148.28, with a high forecast of $178.00 and a low forecast of $90.00. The average price target represents a -15.68% upside from the last price of $175.85.
Hold
The current consensus among 9 investment analysts is to hold stock in Varian Medical Systems. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 3 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 3 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 3 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 3 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 3 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 3 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021UBS GroupDowngradeBuy ➝ In-LineLow
i
2/23/2021UBS GroupDowngradeBuy ➝ In-LineLow
i
12/31/2020UBS GroupDowngradeIn-LineN/A
i
12/14/2020UBS GroupDowngradeIn-LineLow
i
12/7/2020UBS GroupDowngradeBuy ➝ In-LineLow
i
12/7/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$178.00Low
i
12/1/2020UBS GroupDowngradeIn-LineLow
i
11/25/2020UBS GroupDowngradeBuy ➝ In-LineLow
i
11/17/2020UBS GroupDowngradeIn-LineLow
i
11/11/2020UBS GroupDowngradeBuy ➝ In-LineLow
i
11/5/2020UBS GroupDowngradeIn-LineLow
i
10/30/2020UBS GroupDowngradeBuy ➝ In-LineLow
i
10/28/2020Barrington ResearchDowngradeOutperform ➝ UnderperformLow
i
Rating by M. Petusky at Barrington Research
10/28/2020Robert W. BairdDowngradeOutperform ➝ Neutral$178.00Low
i
8/10/2020BTIG ResearchDowngradeBuy ➝ NeutralLow
i
Rating by Marie Thibault at BTIG Research
8/6/2020UBS GroupDowngradeBuy ➝ Neutral$150.00 ➝ $177.50Low
i
8/3/2020Jefferies Financial GroupBoost Price TargetBuy$130.00 ➝ $178.00High
i
8/3/2020BTIG ResearchBoost Price TargetBuy$133.00 ➝ $177.50High
i
Rating by Marie Thibault at BTIG Research
8/2/2020Piper SandlerDowngradeOverweight ➝ Neutral$142.00 ➝ $177.50High
i
Rating by Jason Bednar at Piper Sandler
7/27/2020Piper SandlerBoost Price TargetOverweight$130.00 ➝ $142.00High
i
5/5/2020UBS GroupLower Price TargetBuy$160.00 ➝ $150.00Medium
i
5/5/2020Barrington ResearchReiterated RatingBuy$147.00 ➝ $137.00High
i
Rating by M. Petusky at Barrington Research
5/5/2020Piper SandlerBoost Price TargetOverweight$126.00 ➝ $130.00High
i
5/4/2020BTIG ResearchReiterated RatingBuy$133.00High
i
Rating by Marie Thibault at BTIG Research
4/19/2020Piper SandlerInitiated CoverageOverweight$126.00High
i
4/19/2020Evercore ISIDowngradeOutperform ➝ UnderperformHigh
i
Rating by Vijay Kumar at Evercore ISI
4/17/2020JPMorgan Chase & Co.Lower Price TargetUnderweight$100.00 ➝ $90.00High
i
4/9/2020Evercore ISIDowngradeOutperform ➝ Underperform$163.00 ➝ $105.00Low
i
Rating by Vijay Kumar at Evercore ISI
4/7/2020Piper SandlerInitiated CoverageOverweight$126.00High
i
4/1/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$171.00 ➝ $114.00High
i
3/10/2020BTIG ResearchLower Price Target$157.00 ➝ $143.00High
i
3/10/2020Barrington ResearchLower Price Target$160.00 ➝ $147.00High
i
Rating by M. Petusky at Barrington Research
3/10/2020Robert W. BairdLower Price TargetOutperform$166.00 ➝ $143.00High
i
Rating by Jason Bednar at Robert W. Baird
3/10/2020UBS GroupLower Price TargetBuy$175.00 ➝ $160.00High
i
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$171.00Low
i
1/30/2020Barrington ResearchReiterated RatingOutperform$152.00 ➝ $160.00Low
i
Rating by Michael Petusky at Barrington Research
1/30/2020Robert W. BairdBoost Price TargetOutperform$158.00 ➝ $166.00Low
i
Rating by Jason Bednar at Robert W. Baird
1/24/2020BTIG ResearchReiterated RatingBuy$157.00Medium
i
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$130.00 ➝ $164.00High
i
12/4/2019UBS GroupBoost Price TargetBuy$155.00 ➝ $160.00High
i
11/18/2019Robert W. BairdReiterated RatingBuy$158.00Low
i
Rating by Jason Bednar at Robert W. Baird
10/24/2019Barrington ResearchBoost Price TargetOutperform$146.00 ➝ $152.00High
i
Rating by Michael Petusky at Barrington Research
10/21/2019Barrington ResearchSet Price TargetBuy$146.00High
i
Rating by Michael Petusky at Barrington Research
10/14/2019BTIG ResearchUpgradeNeutral ➝ Buy$130.00Medium
i
Rating by Sean Lavin at BTIG Research
9/23/2019Barrington ResearchBoost Price TargetOutperform$142.00 ➝ $146.00Low
i
7/26/2019Robert W. BairdSet Price TargetBuy$158.00Low
i
Rating by Jason Bednar at Robert W. Baird
7/25/2019Barrington ResearchReiterated RatingBuy$142.00Medium
i
7/24/2019BTIG ResearchReiterated RatingHoldLow
i
Rating by Sean Lavin at BTIG Research
5/2/2019CitigroupLower Price TargetBuy ➝ Buy$174.00 ➝ $165.00Medium
i
4/25/2019UBS GroupBoost Price TargetBuy ➝ Buy$150.00 ➝ $158.00Medium
i
4/4/2019Barrington ResearchBoost Price TargetOutperform$135.00 ➝ $150.00Low
i
3/22/2019Robert W. BairdUpgradeNeutral ➝ Outperform$127.00 ➝ $162.00Low
i
Rating by Jason Bednar at Robert W. Baird
1/24/2019Barrington ResearchReiterated RatingBuyLow
i
1/24/2019BTIG ResearchReiterated RatingHoldLow
i
1/24/2019Royal Bank of CanadaBoost Price TargetSector Perform$130.00Low
i
Rating by Brandon Henry at Royal Bank of Canada
1/24/2019Jefferies Financial GroupBoost Price TargetBuy$145.00Low
i
1/4/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$107.00 ➝ $129.00High
i
1/2/2019CitigroupLower Price TargetBuy ➝ Buy$145.00 ➝ $131.00Low
i
11/28/2018UBS GroupInitiated CoverageBuy$140.00High
i
10/31/2018CitigroupBoost Price TargetBuy ➝ Buy$127.00 ➝ $145.00High
i
10/24/2018JPMorgan Chase & Co.Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $105.00High
i
10/19/2018Robert W. BairdInitiated CoverageNeutral ➝ Neutral$119.00Medium
i
10/4/2018Royal Bank of CanadaSet Price TargetHold$115.00Low
i
Rating by Brandon Henry at Royal Bank of Canada
6/28/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$105.00Medium
i
4/10/2018Royal Bank of CanadaSet Price TargetHold$115.00Low
i
Rating by Brandon Henry at Royal Bank of Canada
1/28/2018BTIG ResearchReiterated RatingNeutral ➝ HoldLow
i
1/25/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $105.00Low
i
1/25/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$130.00High
i
Rating by M. Petusky at Barrington Research
1/25/2018CitigroupBoost Price TargetNeutral ➝ Buy$128.00 ➝ $132.00High
i
1/25/2018Royal Bank of CanadaBoost Price TargetSector Perform$115.00High
i
Rating by Brandon Henry at Royal Bank of Canada
1/25/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$98.00High
i
1/3/2018Evercore ISIInitiated CoverageUnderperform ➝ Underperform$100.00Low
i
11/30/2017Royal Bank of CanadaSet Price TargetHold$105.00Low
i
10/30/2017CitigroupBoost Price TargetNeutral$119.00 ➝ $121.00N/A
i
10/29/2017BTIG ResearchReiterated RatingHoldN/A
i
9/7/2017BTIG ResearchDowngradeBuy ➝ NeutralMedium
i
9/1/2017Royal Bank of CanadaReiterated RatingHold$100.00N/A
i
8/28/2017Robert W. BairdReiterated RatingHold$99.00Low
i
7/14/2017Robert W. BairdReiterated RatingNeutral$89.00 ➝ $99.00Low
i
5/17/2017AegisReiterated RatingHold$91.00Low
i
5/16/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$92.00Low
i
5/15/2017CitigroupUpgradeNeutral ➝ BuyLow
i
5/11/2017Jefferies Financial GroupReiterated RatingBuyLow
i
5/8/2017BTIG ResearchUpgradeNeutral ➝ Buy$106.00High
i
5/8/2017CitigroupUpgradeNeutral ➝ BuyHigh
i
4/27/2017Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Petusky at Barrington Research
4/27/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$82.00 ➝ $90.00High
i
4/24/2017Off Wall StreetInitiated CoverageSellLow
i
2/8/2017Jefferies Financial GroupReiterated RatingBuy$102.00 ➝ $88.00N/A
i
2/6/2017AegisInitiated CoverageHold$85.00N/A
i
1/27/2017Barrington ResearchBoost Price TargetOutperform$98.00 ➝ $102.00N/A
i
1/26/2017Evercore ISIDowngradeHold ➝ Sell$81.50N/A
i
1/23/2017Royal Bank of CanadaSet Price TargetHold$91.00 ➝ $93.00N/A
i
1/23/2017Royal Bank of CanadaBoost Price TargetSector Perform$91.00 ➝ $93.00N/A
i
1/23/2017Royal Bank of CanadaReiterated RatingSector Perform$91.00 ➝ $93.00N/A
i
1/6/2017Royal Bank of CanadaReiterated RatingHoldN/A
i
12/23/2016Jefferies Financial GroupReiterated RatingBuy$102.00N/A
i
12/1/2016Jefferies Financial GroupReiterated RatingBuy$102.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
10/31/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Sean Lavin at BTIG Research
9/28/2016Jefferies Financial GroupReiterated RatingBuy$98.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
9/28/2016Robert W. BairdBoost Price TargetNeutral$91.00 ➝ $99.00N/A
i
7/28/2016Barrington ResearchLower Price TargetOutperform$102.00 ➝ $93.00N/A
i
7/28/2016Morgan StanleyBoost Price TargetUnderweight$80.00 ➝ $86.00N/A
i
Rating by Steve Beuchaw at Morgan Stanley
7/28/2016CitigroupBoost Price TargetNeutral$84.00 ➝ $88.00N/A
i
7/28/2016Brean CapitalBoost Price TargetBuy$87.00 ➝ $90.00N/A
i
Rating by Jason Wittes at Brean Capital
7/28/2016Jefferies Financial GroupBoost Price TargetBuy$95.00 ➝ $98.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
6/23/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jason Wittes at Brean Capital
6/22/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Sean Lavin at BTIG Research
6/10/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
5/24/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
5/24/2016Morgan StanleyReiterated RatingSellN/A
i
Rating by Steve Beuchaw at Morgan Stanley
5/22/2016Brean CapitalReiterated RatingBuy$87.00N/A
i
Rating by Jason Wittes at Brean Capital
4/28/2016Jefferies Financial GroupReiterated RatingBuy$95.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
4/28/2016Brean CapitalBoost Price TargetBuy$82.00 ➝ $87.00N/A
i
3/28/2016Robert W. BairdLower Price TargetOutperform$102.00 ➝ $101.00N/A
i
Rating by Jeff Johnson at Robert W. Baird
3/28/2016Jefferies Financial GroupBoost Price TargetBuy$80.00 ➝ $92.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
3/28/2016Brean CapitalBoost Price TargetBuy$80.00 ➝ $95.00N/A
i
Rating by Jason Wittes at Brean Capital
(Data available from 3/6/2016 forward)
Varian Medical Systems logo
Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment. Its products include linear accelerators, brachytherapy afterloaders, treatment accessories, and quality assurance software; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, medical oncology practices, radiotherapy centers, and cancer care clinics. The Proton Solutions segment designs, develops, manufactures, sells, and services products and systems for delivering proton therapy for the treatment of cancer. The company has a strategic agreement with McKesson Corp. to supply treatment delivery systems and planning, services, and radiotherapy information system solutions to its U.S. Oncology Network and Vantage Oncology affiliated sites of care; and a strategic partnership with Siemens AG to represent Siemens diagnostic imaging products to radiation oncology clinics in the United States and other select markets. Varian Medical Systems, Inc. was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. The company was founded in 1948 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $175.85
$175.40
$175.99

50 Day Range

MA: $175.83
$175.15
$176.40

52 Week Range

Now: $175.85
$89.62
$176.50

Volume

769,594 shs

Average Volume

743,825 shs

Market Capitalization

$16.15 billion

P/E Ratio

60.02

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Varian Medical Systems?

The following sell-side analysts have issued research reports on Varian Medical Systems in the last year: Barrington Research, BTIG Research, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for VAR.

What is the current price target for Varian Medical Systems?

9 Wall Street analysts have set twelve-month price targets for Varian Medical Systems in the last year. Their average twelve-month price target is $148.28, suggesting a possible downside of 15.7%. Robert W. Baird has the highest price target set, predicting VAR will reach $178.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $90.00 for Varian Medical Systems in the next year.
View the latest price targets for VAR.

What is the current consensus analyst rating for Varian Medical Systems?

Varian Medical Systems currently has 3 sell ratings and 6 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VAR, but not buy more shares or sell existing shares.
View the latest ratings for VAR.

What other companies compete with Varian Medical Systems?

How do I contact Varian Medical Systems' investor relations team?

Varian Medical Systems' physical mailing address is 3100 Hansen Way, Palo Alto CA, 94304. The medical equipment provider's listed phone number is 650-493-4000 and its investor relations email address is [email protected] The official website for Varian Medical Systems is www.varian.com.